Search

Your search for "POAI" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Present at Three Upcoming Events

February 22, 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be represented at three upcoming conferences: the BIO CEO & Investor Conference, the 2024 NeauxCancer Oncology Conference and H.C. Wainwright’s first Artificial Intelligence Based Drug Discovery & Development virtual conference. According to the announcement, POAI CEO Raymond F. Vennare will […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Participation in January Conferences

January 2, 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, will be attending three upcoming conferences: Biotech Showcase, LifeSco Partners Corporate Access Event and BIO Partnering@JPM Week 2024. All three events are slated for Jan. 8–10, 2024, in San Francisco. According to the announcement, POAI CEO Raymond F. Vennare will be […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 2023 Financial Results, Business Update

November 14, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, is reported its financial and operating results for the three- and nine-month periods ending Sept. 30, 2023. Highlights of the […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), UPMC Magee-Womens Hospital Complete Ovarian Cancer Study

November 8, 2023

Predictive Oncology (NASDAQ: POAI), a leader in artificial intelligence (“AI”)-driven drug discovery and biologics, has completed a multiyear study through a partnership with UPMC Magee-Womens Hospital. The study was focused on evaluating the use of AI in building multiomic machine learning (“ML”) models and then testing the models to determine if they could learn associations between […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Schedules Release of Q3 Results, Corporate Update Call

November 7, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is planning to release its financial results for Q3 2023. The company announced it […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 2023 Financial Results, Corporate Update

August 11, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is reporting on its Q2 2023 performance. The company reported financial and operating results […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Plans to Release Q2 2023 Financial Results, Host Earnings Call

August 3, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development will report its financial results next week. The company announced that it will release […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Moves Corporate HQ to Pittsburgh

July 18, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, is moving to Pittsburg. The company announced that it has relocated […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Finance Veteran as Newest Business Advisory Board Member

June 27, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine-learning capabilities, its extensive biorepository of tumor samples, and its Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development, has appointed a new member to its business advisory board. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Advisory Board Appointment of Dr. Bernard A. Harris, Jr.

June 20, 2023

Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development. The company today announced the appointment of Dr. Bernard A. Harris, Jr. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Present Groundbreaking PEDAL Approach at 2023 BIO International Convention

May 23, 2023

Predictive Oncology (NASDAQ: POAI) today announced that its Chief Business Officer Pamela Bush, Ph.D., MBA will present at the upcoming 2023 BIO International Convention, in Boston, Massachusetts, on June 5, 2023. Dr. Bush, beginning at 2:45 p.m. ET in presentation room 103, will discuss the importance of addressing patient heterogeneity in drug discovery and the […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2023 Financial Report, Business Update

May 16, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence (“AI”) and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the three months ended March 31, 2023. According to the report, […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Report First Quarter 2023 Results, Host Conference Call and Webcast

May 8, 2023

Predictive Oncology (NASDAQ: POAI) is a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (“CLIA”) laboratory and Good Manufacturing Practices (“GMP”) facility to accelerate oncology drug discovery and enable drug development. The company today announced that it will report its financial results for […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Seasoned Veteran as New Board Member

May 3, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, announced the appointment of a new board member. healthcare commercial and business development veteran Veena Rao, PhD., MBA, will be serving […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Reverse Stock Split Approved, Effective April 24

April 21, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a reverse stock split of its common stock. According to the announcement, the stock split will be effective Monday, […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Special Meeting of Stockholders Rescheduled after ‘Lack of Required Quorum’

April 18, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has adjourned its Special Meeting of stockholders. The company held the meeting on April 17, 2023, at 3 p.m., and then […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Oncology Translational Research Leader to Scientific Advisory Board

April 4, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has appointed Christoph Reinhard, PhD, MBA, to its Scientific Advisory Board. Reinhard will join other board members who are thought leaders […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Integra Therapeutics Collaborate to Advance Gene Therapy

March 30, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to the announcement, the collaboration was created to pursue a novel method to […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates to Leverage AI for New Cancer Drugs, Announces 2022 Results

March 22, 2023

Predictive Oncology’s (NASDAQ: POAI) chief business officer Pamela Bush and Dom Pollard, business development manager at Cancer Research Horizons, joined Proactive’s Natalie Stoberman to discuss their partnership for new cancer drug development. According to the announcement, “The collaboration will utilize Predictive Oncology’s PEDAL technology [an artificial intelligence (‘AI’) and machine learning platform] to evaluate Cancer […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Key Partnership, Declares Dividend

March 17, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is collaborating with Cancer Research Horizons in the development of oncology drugs utilizing its proprietary PEDAL(TM) platform. Cancer Research Horizons is the […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Engages with Leading IR Consultant to Implement Comprehensive IR Effort

March 14, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a new partnership. The company is working with LifeSci Advisors to implement a comprehensive IR program. The company anticipates […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Updates Shareholders, Provides Company Overview and Plans for Future

March 9, 2023

Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare has issued a letter to shareholders, providing an overview of the company and a look at the significant progress the company has made in respect to validating its commercial platform and publishing its proof of concept. In the letter, Vennare noted that Predictive Oncology is now in a […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Talks New Cvergenx Partnership During Proactive Interview

March 1, 2023

Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare was a featured guest during the latest interview released by Proactive US. Vennare joined Cvergenx CEO Javier Torres-Roca to talk about the recent announcement that the two companies have joined forces to create a new genomic-based artificial intelligence (“AI”) radiation therapy. Host Natalie Stoberman facilitated the discussion, in […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Cvergenx Inc. to Collaborate in Novel Approach to Personalized Radiotherapy and Drug Discovery

February 23, 2023

Predictive Oncology (NASDAQ: POAI) and Cvergenx today announced an agreement to form a strategic partnership that will potentially revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery. According to the announcement, the collaboration’s objective is to leverage and maximize the combined power of proprietary technologies […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Chief Business Officer

February 22, 2023

Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery, has announced the appointment of a new chief business officer. The company has named veteran Pamela Bush to the role. Bush was featured during a recent Proactive video release, during which she and host Natalie Stoberman discussed her new assignment. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Program to Partner Academic, Research Institutions to Assist with Drug-Discovery Initiatives

February 21, 2023

Predictive Oncology (NASDAQ: POAI) launched a program designed to advance the oncology drug-development initiatives with academic and research institutions. The program, called ACE, partners with early-stage academic and research institutions to assist in advancing their efforts and focus on drug discovery. The program provides access to POAI’s PEDAL platform, which brings together active machine learning with […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer

February 3, 2023

Predictive Oncology (NASDAQ: POAI) has announced a new chief business officer. Effective immediately, Pamela Bush, PhD, MBA, will take on the role as chief business officer and will oversee all business development including the partnering and growth strategies for the company. Specifically, the company observed that she will manage the company’s strategic, operational and financial […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Computational Biology Pioneer as New Scientific Advisory Board Member

January 12, 2023

Predictive Oncology (NASDAQ: POAI) has announced a new member of its Scientific Advisory Board: Robert F. Murphy, PhD, a pioneer in the field of machine learning and analytics for biological data, will be joining the board and working with other experts in a variety of fields to guide the POAI’s scientific initiatives and growth strategy. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Expands Scientific Advisory Board to Appoint Genomics Expert

December 13, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of Marc Malandro, Ph.D., to the company’s scientific advisory board. Dr. Malandro, a highly regarded scientific leader and expert in genomics, molecular biology, biochemistry and bioengineering, will serve alongside other key thought […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Member

December 5, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initiatives and commercialization efforts.” A well-known business executive in the pharma and biotech industries, Hawryluk currently serves as executive vice […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q3 Financial Report, Corporate Update

November 11, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting corporate updates and financial results for its Q3 quarter, ended Sept. 30, 2022. According to the announcement, the report reflects revenue growth and increased gross profit margin as compared to prior year periods. Highlights […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Key Life Sciences Thought Leader to Its Board

October 25, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its appointment of David S. Smith, JD, to the company’s board of directors. Smith is a life sciences and corporate attorney, veteran biotech industry executive and leading authority on the legal issues surrounding the […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Seasoned Senior Exec, Biotech Entrepreneur as New CEO

October 20, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Raymond F. Vennare as its new chief executive officer, effective Nov. 1, 2022; Vennare will also assume the role of board chair. Vennare has more than 30 years’ experience building and leading biotechnology and […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report

August 12, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ended June 30, 2022. In addition, the company also released a corporate update for the company, […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Q2 Financial Report

August 12, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its numbers for second quarter 2022, or the period ended June 30, 2022. According to the announcement, the report indicates a strong balance sheet with a solid cash balance, commensurate equity and no debt. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Names Chief Scientific Officer, Shares R&D Update

July 26, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Julia Kirshner, PhD, as its new chief scientific officer. Kirshner has been serving as POAI’s senior vice president as well as president of the company’s zPREDICTA division, a company that she originally founded in […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.2M in Registered Direct Offerings

May 19, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on two direct offerings. The offerings, which were available concurrently, were with different institutional investors and results in approximately $7.2 million in gross proceeds for the company, before the deduction of […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.2M Registered Direct Offerings

May 16, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional investors for the issuance and sale of shares of its common stock, with related agreements regarding certain stock purchase warrants, in connection with two concurrent offerings. […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases Q1 Financial Report, Corporate Update

May 13, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released financial results from its first quarter, the period ending March 31, 2022. Highlights from the report include recognized revenue of $314,568 for the quarter, up from $280,317 reported for the same period in 2021; […]

InvestorNewsBreaks

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Experienced Leader as Senior Director of Marketing

April 26, 2022

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop optimal cancer therapies, today announced that Theresa Ferguson has been named senior director of marketing. As the company’s senior marketing leader, Ferguson steps in as Predictive Oncology begins commercialization of its knowledge-driven technologies, applying artificial intelligence (“AI”) to develop personalized […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).